In this context, GLP-1RAs can inhibit the secretion of IL-2 and interferon (IFN)-, thereby regulating the immune microenvironment and preventing diabetes [144]
It plays a pivotal role in energy balance and postprandial metabolism by enhancing glucose-dependent insulin secretion, suppressing glucagon release, delaying gastric emptying, and promoting satiety through central mechanisms [8, 9]
While there is no medically mandated best time that applies universally, many providers recommend taking your first injection in the morning or shortly after a meal
In March 2026, topline results from the TRANSCEND-T2D-1 trials showed that participants with Type 2 diabetes achieved an average A1C reduction of up to 2.0% and lost nearly 17% of their body weight over 40 weeks
by Jennifer Lines, PharmD Candidate, PCCA Clinical Services Intern, and Catherine Henderson, PharmD, PCCA Clinical Compounding Pharmacist Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized metabolic health and weight management, leading to a host of new weight loss wonder drugs
They do so by stimulating the release of insulin, slowing down the emptying of the stomach, and reducing the production of glucose by the liver
